血清β2-糖蛋白Ⅰ及还原型β2-糖蛋白Ⅰ与糖尿病肾病关系的研究  

Study of the relationship between serum β2-GPⅠ/reduced β2-GPⅠ and diabetic nephropathy

作　　者：王彤[1] 于德民[1] 于珮[1] 

机构地区：[1]天津医科大学代谢病医院糖尿病肾病血液透析科 卫生部激素与发育重点实验室,300070

出　　处：《中华临床医师杂志（电子版）》2014年第21期22-26,共5页Chinese Journal of Clinicians(Electronic Edition)

基　　金：天津市科技支撑重点项目(13ZCZDSY01300)

摘　　要：目的探讨血清β2-糖蛋白Ⅰ(β2-GPⅠ)及还原型β2-GPⅠ水平与糖尿病肾病(DN)的关系及其临床意义。方法选取2型糖尿病患者231例,分为单纯糖尿病组62例、早期DN组61例、临床DN肾功能正常组56例以及临床DN肾功能不全组52例,同时选取门诊健康体检者52例,用酶联免疫吸附试验(ELISA)检测血清β2-GPⅠ及还原型β2-GPⅠ水平,测定空腹血糖(FPG)、糖化血红蛋白(HbA1c)、血肌酐(Scr)、血尿素氮(BUN)和24 h尿白蛋白定量,计算尿白蛋白排泄率(UAER),并做相关与回归分析。结果糖尿病各组β2-GPⅠ及还原型β2-GPⅠ水平均显著高于对照组(P<0.05);除临床DN肾功能不全组β2-GPⅠ水平显著高于单纯糖尿病组(P<0.05)外,糖尿病各组间β2-GPⅠ水平差异无统计学意义(P>0.05);各组还原型β2-GPⅠ水平依次增高(P<0.05),临床DN肾功能不全组与临床DN肾功能正常组还原型β2-GPⅠ水平差异无统计学意义(P>0.05);还原型β2-GPⅠ水平与β2-GPⅠ水平及UAER呈显著正相关(r=0.324、0.418,P<0.01);还原型β2-GPⅠ、Scr、BUN是UAER的危险因素。结论还原型β2-GPⅠ水平与DN的进程有一定的相关关系,且可作为UAER的独立危险预测因素。Objective To investigate the correlation of serum beta2-glycoprotein I （β2-GP I ） and reduced β2-GP I levels between patients with diabetic nephropathy （DN） and type 2 diabetes meUitus （T2DM）. Methods Serum samples were collected from 231 T2DM patients who were treated at Department of Geriatrics in Tianjin Medical University Metabolic Diseases Hospital from November 2012 to May 2014, 52 cases of health volunteers were also included in this study as control normal group （CN）. According to the levels of urinary albumin excretion rates （UERA） and serum creatinin （Scr）, the T2DM patient were enrolled into 4 groups： simple T2DM group （62 cases）, early DN group （61 cases）, clinical DN group （56 cases） and clinical DN combining with renal insufficiency group （52 cases）. Serum β2-GP I and reduced β2-GP I were measured by enzyme-linked immunosorbent assay （ELISA）, and fasting plasma glucose （FPG）, Set, blood urea nitrogen （BUN）, HbAlc, 24 hours urinary albumin and UAER were determined and analyzed. Results The levels of serum β2-GP I and reduced β2-GP I in T2DM patients were significant higher than that in control group （P〈0.05）. The difference levels of β2-GP I between T2DM groups were not statistical significant （P〉0.05）, except that the levels of β2-GP I were significantly higher in,the clinical DN combining with renal insufficiency group compared with the simple T2DM group （P〈0.05）. The levels of reduced β2-GP I in each group increased in turn （P〈0.05）, except that there was no difference between clinical DN group combining with or without renal insufficiency group （P〉0.05）. Serum reduced β2-GP i levels was positively correlated with serum β2-OP I levels and UAER （r=0.324, 0.418, P〈0,01）, Reduced β2-GP I, Scr and BUN were the risk factors of UAER, Coneluslon Serum reduced β2-GP I may play an important role in the development of DN and is independent risk factors of UAER,

关 键 词：糖尿病 2型 糖尿病肾病 β2-糖蛋白Ⅰ 还原型β2-糖蛋白Ⅰ 

分 类 号：R587.2[医药卫生—内分泌] R692[医药卫生—内科学]